Skip to main content

Targeted contrast agents to better detect pancreatic tunor and its zinc content by MRI on mice

Project description

Determining zinc content in cancer with MRI

Prompt diagnosis and therapies for pancreatic cancer are limited, leading to a dismal prognosis and low survival rate. Emerging evidence indicates that pancreatic cancer cells present low levels of zinc importers and zinc content, while treatment with the zinc ionophore clioquinol inhibits tumour growth. The EU-funded tZR-CA-InVivo project aims to develop a magnetic resonance imaging tool, namely a zinc-responsive contrast agent to quantify zinc content in tissues. The contrasting agent will be designed to specifically target the tumour and provide a means for monitoring zinc levels in patients with cancer and evaluate the need to increase it.

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution
€ 196 707,84
Address
Rue Michel Ange 3
75794 Paris
France
Activity type
Research Organisations
Non-EU contribution
€ 0,00